Browse ITGA9

Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF01839 FG-GAP repeat
PF08441 Integrin alpha
Function

Integrin alpha-9/beta-1 (ITGA9:ITGB1) is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin.

> Gene Ontology
 
Biological Process GO:0007229 integrin-mediated signaling pathway
GO:0030198 extracellular matrix organization
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0043062 extracellular structure organization
GO:0050900 leukocyte migration
GO:0060326 cell chemotaxis
GO:0071621 granulocyte chemotaxis
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1990266 neutrophil migration
Molecular Function GO:0005518 collagen binding
GO:0043236 laminin binding
GO:0050840 extracellular matrix binding
Cellular Component GO:0008305 integrin complex
GO:0009925 basal plasma membrane
GO:0016323 basolateral plasma membrane
GO:0034679 integrin alpha9-beta1 complex
GO:0043235 receptor complex
GO:0045178 basal part of cell
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04514 Cell adhesion molecules (CAMs)
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-216083: Integrin cell surface interactions
R-HSA-373760: L1CAM interactions
R-HSA-445144: Signal transduction by L1
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITGA9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITGA9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITGA9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4340.326
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4450.664
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4370.642
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0690.859
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2570.893
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1690.943
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2920.47
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7310.541
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2690.85
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5490.555
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9590.0839
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1950.192
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITGA9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1032033.3-13.31
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.6028.60.0241
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.8030.80.0983
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGA9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGA9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGA9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGA9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITGA9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITGA9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITGA9
Nameintegrin, alpha 9
Aliases RLC; ITGA4L; ALPHA-RLC; integrin, alpha 4-like; integrin alpha-RLC; Integrin alpha-9
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITGA9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.